
Please try another search
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Dean Jonathan Mitchell | 66 | 2020 | Independent Chairman of the Board |
Jeffrey Allan Chodakewitz | 66 | 2021 | Independent Director |
Gregory Norden | 64 | 2019 | Independent Director |
William D. Young | 77 | 2016 | Independent Director |
Jill DeSimone | 67 | 2022 | Independent Director |
Samuel F. Berkovic | - | 2023 | Member of Scientific Advisory Board |
Merit E. Cudkowicz | 60 | 2021 | Independent Director |
Anna Greka | - | 2023 | Member of Scientific Advisory Board |
Ivan Soltesz | - | 2023 | Member of Scientific Advisory Board |
Matthew Might | - | 2023 | Chairman of the Scientific Advisory Board |
Holger Lerche | - | 2023 | Member of Scientific Advisory Board |
Marcio Silva De'Souza | 44 | 2020 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review